Somewhat Positive News Coverage Somewhat Unlikely to Impact Alcobra (ADHD) Stock Price

Press coverage about Alcobra (NASDAQ:ADHD) has been trending somewhat positive this week, Accern Sentiment Analysis reports. The research firm identifies positive and negative press coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Alcobra earned a daily sentiment score of 0.15 on Accern’s scale. Accern also assigned headlines about the biotechnology company an impact score of 46.0830777666785 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.

Here are some of the news headlines that may have effected Accern Sentiment Analysis’s rankings:

Several equities analysts have recently issued reports on the company. WBB Securities upgraded Alcobra from a “hold” rating to a “buy” rating and set a $2.00 price target on the stock in a research note on Monday, October 9th. Zacks Investment Research upgraded Alcobra from a “hold” rating to a “buy” rating and set a $1.25 price target on the stock in a research note on Wednesday, October 4th. Finally, Roth Capital downgraded Alcobra from a “buy” rating to a “neutral” rating and cut their price objective for the company from $4.00 to $1.00 in a report on Friday, September 29th. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating and one has issued a buy rating to the company. The stock presently has an average rating of “Hold” and an average price target of $1.50.

Shares of Alcobra (NASDAQ:ADHD) traded up $0.05 on Tuesday, reaching $1.44. The company’s stock had a trading volume of 236,000 shares, compared to its average volume of 666,198. Alcobra has a 52-week low of $0.83 and a 52-week high of $2.58.

Alcobra (NASDAQ:ADHD) last posted its quarterly earnings data on Friday, August 11th. The biotechnology company reported ($0.13) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.15) by $0.02. equities analysts anticipate that Alcobra will post -0.41 earnings per share for the current fiscal year.

WARNING: This report was originally reported by Transcript Daily and is the property of of Transcript Daily. If you are reading this report on another publication, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The original version of this report can be read at

Alcobra Company Profile

Alcobra Ltd is a development-stage biopharmaceutical company. The Company is focused on development and commercialization of its lead product candidates, including MDX and ADAIR. MDX is a oral drug, for the treatment of ADHD and other cognitive disorders, including Fragile X. MDX is a combined rapid onset ER formulation of the chemical pyridoxine pyroglutamate, which is more commonly known as metadoxine.

Insider Buying and Selling by Quarter for Alcobra (NASDAQ:ADHD)

Receive News & Ratings for Alcobra Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alcobra Ltd. and related companies with's FREE daily email newsletter.

Leave a Reply